Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients.

Archives of dermatological research - 1 Jul 2015

González-Lara Leire, Batalla Ana, Coto Eliecer, Gómez Juan, Eiris Noemí, Santos-Juanes Jorge, Queiro Rubén, Coto-Segura Pablo

Abstract excerpt

Genetic factors are involved not only in the overall risk of suffering psoriasis, but also in their clinical characteristics and eventually in drug outcome. Biological therapies have dramatically improved the prognosis of Psoriasis. However, these treatments are very expensive and patients often exhibit a heterogeneous response that could be partially attributed to their genetic background. Thus, the research for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance
Share to TNF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation, Missense

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Psoriasis

Share to Receptors, Tumor Necrosis Factor, Type II

Share to Sequence Analysis, Protein

Source

Identifiers

PMID: 25537528
DOI: 10.1007/s00403-014-1533-z

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients.PMID 25537528Read ↗

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.Semantic proximity Read ↗

Genetic prediction of the effectiveness of biologics for psoriasis treatment.Semantic proximity Read ↗

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.Semantic proximity Read ↗

Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.Semantic proximity Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.Semantic proximity Read ↗

Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe PsoriasisSemantic proximity Read ↗

Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.Semantic proximity Read ↗

Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study.Semantic proximity Read ↗

CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients.Semantic proximity Read ↗

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.